Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease (PHOTON)
A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema
Sponsor: Bayer
This PHASE2/PHASE3 trial investigates Diabetic Macular Edema and Type 1 Diabetes Mellitus and is currently completed. Bayer leads this study, which shows 15 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Status: Active Not Recruiting → Completed
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Dec 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2_PHASE3
▶ Show 10 earlier versions
-
Jun 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Dec 2022 — Jun 2023 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jul 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jun 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Oct 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2021 — Oct 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2021 — Jun 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jul 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Jun 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- Regeneron Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .